Search results for "Adverse effect"

showing 10 items of 1065 documents

Aceclofenac versus naproxen in the treatment of ankylosing spondylitis: A double-blind, controlled study

1994

Abstract The efficacy and tolerability of aceclofenac and naproxen sodium in the treatment of ankylosing spondylitis (AS) were evaluated and compared in this double-blind, multicenter, controlled study. Of the 130 patients who entered the study, 126 patients met the inclusion criteria. Efficacy was evaluated at baseline, 15 days, and 1, 2, and 3 months using a visual analog scale for spontaneous pain, a zero to three-point scale for pain on movement and pain at rest, and measurements of chest expansion, hand-to-floor distance, Schober's test, and normal daily activities. No significant between-group differences were seen for any of the variables at baseline, except hand-to-floor distance. B…

PharmacologyAnkylosing spondylitisNaproxenmedicine.medical_specialtybusiness.industryVisual analogue scaleIncidence (epidemiology)Naproxen Sodiummedicine.diseaseTolerabilityAnesthesiaPhysical therapyMedicineAceclofenacPharmacology (medical)businessAdverse effectmedicine.drugCurrent Therapeutic Research
researchProduct

Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstruct…

1998

Abstract The aims of management in mild-to-moderate stable chronic obstructive pulmonary disease (COPD) are to improve symptoms and quality of life (QOL), reduce decline in lung function, prevent and treat complications, increase survival while maintaining QOL, and minimize the adverse effects of treatment. Bronchodilator therapy is the keystone of improving COPD symptoms and functional capacity. The primary objective of this open-label study was to compare the efficacy and tolerability of salmeterol 50 μg BID administered by metered-dose inhaler versus oral, titrated, sustained-release theophylline BID, both given for 3 months to patients with a clinical history of chronic bronchitis. The …

PharmacologyCOPDChronic bronchitismedicine.drug_classbusiness.industrymedicine.diseaseTolerabilityBronchodilatorAnesthesiamedicineSalbutamolPharmacology (medical)TheophyllineSalmeterolAdverse effectbusinessmedicine.drugClinical Therapeutics
researchProduct

Aceclofenac cream versus piroxicam cream in the treatment of patients with minor traumas and phlogistic affections of soft tissues: a double-blind st…

1995

Abstract The efficacy and safety of aceclofenac 1.5% cream and piroxicam 1% cream in 220 patients with soft-tissue injuries were evaluated in a double-blind, randomized, multicenter, comparative, parallel-group trial. Patients were randomly assigned to each treatment group to receive therapy three times a day for 7 days. The primary outcome measure of pain was evaluated using a visual analog scale (VAS) at baseline, day 4, and day 7 of the study. Safety was assessed by recording any adverse events that occurred and by monitoring any hemato-biochemical alterations during the study. After days 4 and 7 of treatment, a significant improvement ( P P

PharmacologyChemotherapymedicine.medical_specialtyRandomizationbusiness.industryVisual analogue scalemedicine.medical_treatmentSoft tissuePiroxicamSurgeryDouble blind studyAnesthesiaMedicineAceclofenacPharmacology (medical)businessAdverse effectmedicine.drugCurrent Therapeutic Research
researchProduct

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system

2019

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm in which clonal proliferation of hematopoietic stem cells and bone marrow fibrosis coexist.1 Patients may eventually die due to leukemic progression, which occurs in up to 20% of cases, or because of cardiovascular comorbidities or cytopenia, which causes susceptibility to infections and bleeding.2 Myelofibrosis diagnosis relies upon the evaluation of several clinical and laboratory criteria suggested by the World Health Organization (WHO) in 2016.3 The major mutations leading to myelofibrosis usually occur in the JAK2, CALR, and MPL genes. However, in almost 10% of the cases, none of the above-mentioned mutations can be detected …

PharmacologyCytopeniamedicine.medical_specialtyRuxolitinibbusiness.industryIPSSruxolitinibprimary myelofibrosilcsh:RM1-950Case ReportGeneral Medicinemedicine.diseaseDiscontinuationPolycythemia veralcsh:Therapeutics. PharmacologyInternational Prognostic Scoring SystemInternal medicinemedicineprimary myelofibrosisMolecular MedicineMyelofibrosisAdverse effectbusinessMyeloproliferative neoplasmmedicine.drugDrugs in Context
researchProduct

Correlación, en pacientes infectados por el VIH-1 y previamente tratados, entre la reacción de hipersensibilidad a abacavir y el alelo HLA-B*5701

2009

Introduction: Hypersensitivity reaction to abacavir (a powerful inverse transcriptase inhibitor) is a serious adverse effect that limits its use in antiretroviral treatment and requires a high level of clinical surveillance. Certain haplotypes of the primary histocompatibility complex proteins (HLA-B*5701) are very signifi cant predictors of the risk of hypersensitivity to this drug. The purpose of this study is to identify the cases where a probable hypersensitivity reaction to abacavir presented the HLA-B*5701 allele. Method: A retrospective study was conducted in all HIV-1 positive adult patients infected treated with abacavir between January 2000 and December 2007, in Department 6 of th…

PharmacologyDrugmedicine.medical_specialtyAdult patientsbusiness.industrymedia_common.quotation_subjectRetrospective cohort studyGastroenterologyRashSurgeryHypersensitivity reactionAbacavirInternal medicineAntiretroviral treatmentMedicinemedicine.symptombusinessAdverse effectmedia_commonmedicine.drugFarmacia Hospitalaria
researchProduct

Modulation of the pharmacokinetics, therapeutic and adverse effects of NSAIDs by Chinese herbal medicines.

2014

Concomitant use of NSAIDs and Chinese herbal medicines (CHMs) is frequent, yet summarized information on their interactions is lacking.A systematic review of literature in four evidence-based English databases was performed. Articles which reported CHMs altering the pharmacokinetics, therapeutic and adverse effects of NSAIDs were identified and summarized. Such interactions may lead to beneficial, detrimental or no change in outcomes. The current review covers four therapeutic effects of NSAIDs, including: i) anti-inflammatory; ii) analgesic; iii) antiplatelet, cardiovascular and cerebrovascular; and iv) anticancer effects and four adverse effects of NSAIDs, including: i) gastrointestinal u…

PharmacologyHerb-drug interactionsbusiness.industryAnalgesicTherapeutic effectAnti-Inflammatory Agents Non-SteroidalHerb-Drug InteractionsGeneral MedicinePharmacologyToxicologyRisk Assessmentdigestive system diseasesNephrotoxicityPharmacokineticsMedicineAnimalsHumansGastrointestinal ulcerbusinessAdverse effectDrugs Chinese HerbalExpert opinion on drug metabolismtoxicology
researchProduct

Levetiracetam in the treatment of vascular chorea: a case report

2004

PharmacologyLevetiracetam Hemichoreabusiness.industryPharmacology toxicologyChoreaGeneral MedicineBioinformaticsMedicinePharmacology (medical)Levetiracetammedicine.symptombusinessAdverse effectmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

549 An RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma pat…

2021

BackgroundLipo-MERIT is an ongoing, first-in-human, open-label, dose-escalation Phase I trial investigating safety, tolerability and immunogenicity of BNT111 in patients with advanced melanoma. BNT111 is an RNA-LPX vaccine targeting the melanoma tumor-associated antigens (TAAs) New York esophageal squamous cell carcinoma 1 (NY-ESO-1), tyrosinase, melanoma-associated antigen 3 (MAGE-A3), and transmembrane phosphatase with tensin homology (TPTE). A previous exploratory interim analysis showed that BNT111, alone or combined with immune checkpoint inhibition (CPI), has a favorable adverse event (AE) profile, gives rise to antigen-specific T-cell responses and induces durable objective responses…

PharmacologyOncologyCancer Researchmedicine.medical_specialtybusiness.industryImmunogenicityELISPOTMelanomaImmunologyInterim analysismedicine.diseaseVaccinationOncologyTolerabilityInternal medicineCutaneous melanomamedicineMolecular MedicineImmunology and AllergyAdverse effectbusinessJournal for ImmunoTherapy of Cancer
researchProduct

A Systematic Review of Systematic Reviews on the Use of Aromatase Inhibitors for the Treatment of Endometriosis: The Evidence to Date

2023

Endometriosis is a chronic gynecologic condition that affects around 6-10% of reproductive age women. This clinical entity is characterized with pelvic pain, dysmenorrhea, dyspareunia, and infertility which are the most often presenting symptoms. Aromatase P450 is the key enzyme for ovarian estrogen biosynthesis and there is evidence that endometriotic lesions express aromatase and are able to synthesize their own estrogens. Aromatase inhibitors (AIs) are potent drugs that suppress the estrogen synthesis via suppression of aromatase. We performed a systematic review of systematic reviews and narrative reviews on the use of aromatase inhibitors in the medical management of endometriosis. We …

PharmacologySystematic review.Pelvic painpresenze.accessorio(at)unipa.itDrug DiscoveryPharmaceutical ScienceEndometriosiAdverse effectSettore MED/40 - Ginecologia E OstetriciaDrug Design, Development and Therapy
researchProduct

Interferon-?? Alone versus Interferon-?? plus Ribavirin in Patients with Chronic Hepatitis C Not Responding to Previous Interferon-?? Treatment

2000

Objective: To study the effects of monotherapy with leucocyte interferon-α (IFNα) versus IFNα + ribavirin in patients with chronic hepatitis C who were nonresponders to previous courses of recombinant or lymphoblastoid IFNα. Design and setting: This was a nonblind randomised study of outpatients at 3 centres in Palermo, Sicily, Italy. Patients and participants: We recruited 72 patients (48 males, 24 females), mean age 48.8 ± 6.6 years (range 31 to 63 years), with biopsy-proven chronic hepatitis C, predominantly genotype lb. Interventions: 24 patients (group A) received IFNα 6MU 3 times weekly for 6 months, and 48 patients (group B) received IFNα 6MU 3 times weekly + ribavirin 1200 mg/day fo…

Pharmacologymedicine.medical_specialtyCombination therapybusiness.industryRibavirinHepatitis C virusAlpha interferonGeneral Medicinemedicine.disease_causeGastroenterologydigestive system diseasesGroup Bchemistry.chemical_compoundchemistryInterferonInternal medicineAbsolute neutrophil countMedicinePharmacology (medical)businessAdverse effectBiotechnologymedicine.drugBioDrugs
researchProduct